Referencia número: HY-10180

Copy Link Print Information

MLN8054

10 Cited Publications

Revisión del cliente

Based on 10 publication(s) in Google Scholar

MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC₅₀ of 4 nM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.01%
No. CAS: 869363-13-3
Fòrmula: C₂₅H₁₅ClF₂N₄O₂
Peso molecular:476.86

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

MLN8054 Chemical Structure

No. CAS: 869363-13-3

Tamaño

Precio

Stock

Cantidad

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtener un presupuesto Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtener un presupuesto Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Consulta para venta a granel

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (10)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Bioz

Actividad biológica

Descripciòn

MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC₅₀ of 4 nM.

IC₅₀ & Target^[1]

Aurora A

4 nM (IC₅₀)

Ver todos los productos específicos de isoformas Aurora Kinase :

Cellular Effect

Cell Line	Type	Value	Description	References
Calu-6	IC₅₀	0.22 μM Compound: MLN-8054	Antiproliferative activity against human Calu6 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human Calu6 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
DLD-1	IC₅₀	1.43 μM Compound: MLN-8054	Antiproliferative activity against human DLD1 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human DLD1 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
HCT-116	GI₅₀	0.22 μM Compound: 8, MLN8054	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation by BrdU incorporation assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation by BrdU incorporation assay	[PMID: 26101564]
HCT-116	IC₅₀	0.1 μM Compound: 1, MLN-8054	Antiproliferative activity against human HCT116 cells after 4 days by celltiter assay Antiproliferative activity against human HCT116 cells after 4 days by celltiter assay	[PMID: 19402633]
HCT-116	IC₅₀	0.16 μM Compound: 1, MLN-8054	Inhibition of Aurora A in human HCT116 cells assessed as complete failure of centrosome seperation by immunofluorescence assay Inhibition of Aurora A in human HCT116 cells assessed as complete failure of centrosome seperation by immunofluorescence assay	[PMID: 19402633]
HCT-116	IC₅₀	0.18 μM Compound: MLN-8054	Antiproliferative activity against human HCT116 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human HCT116 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
HCT-116	IC₅₀	0.31 μM Compound: 1, MLN-8054	Inhibition of Aurora A in human HCT116 cells assessed as complete loss of phospho-Aurora A staining in centrosomes by immunofluorescence assay Inhibition of Aurora A in human HCT116 cells assessed as complete loss of phospho-Aurora A staining in centrosomes by immunofluorescence assay	[PMID: 19402633]
HCT-116	IC₅₀	0.69 μM Compound: MLN8054	Cytotoxicity against human HCT116 cells after 5 days by MTS assay Cytotoxicity against human HCT116 cells after 5 days by MTS assay	[PMID: 22326168]
HCT-116	IC₅₀	0.85 μM Compound: MLN8054	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30143423]
HCT-116	IC₅₀	34 nM Compound: 4, MLN-8054	Inhibition of aurora A autophosphorylation in human HCT116 cells by immunofluorescence method Inhibition of aurora A autophosphorylation in human HCT116 cells by immunofluorescence method	[PMID: 19320489]
HCT-116	IC₅₀	34 nM Compound: 8, MLN8054	Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysis Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysis	[PMID: 26101564]
HCT-116	IC₅₀	4 μM Compound: 4, MLN-8054	Inhibition of aurora B in human HCT116 cells assessed as inhibition of histone H3 Ser10 phosphorylation by immunofluorescence method Inhibition of aurora B in human HCT116 cells assessed as inhibition of histone H3 Ser10 phosphorylation by immunofluorescence method	[PMID: 19320489]
HCT-116	IC₅₀	5 μM Compound: 1, MLN-8054	Inhibition of Aurora B in human HCT116 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay Inhibition of Aurora B in human HCT116 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay	[PMID: 19402633]
HCT-116	IC₅₀	5.2 μM Compound: 8, MLN8054	Inhibition of aurora kinase B in human HCT116 cells assessed as inhibition of histone H3 phosphorylation by immunofluorescence analysis Inhibition of aurora kinase B in human HCT116 cells assessed as inhibition of histone H3 phosphorylation by immunofluorescence analysis	[PMID: 26101564]
HeLa	IC₅₀	0.034 μM Compound: MLN-8054	Inhibition of Aurora A Thr288 autophosphorylation in human HeLa cells after 1 hr Inhibition of Aurora A Thr288 autophosphorylation in human HeLa cells after 1 hr	[PMID: 17360485]
HeLa	IC₅₀	5.7 μM Compound: MLN-8054	Inhibition of Aurora B Ser10 phosphorylation in human HeLa cells after 1 hr Inhibition of Aurora B Ser10 phosphorylation in human HeLa cells after 1 hr	[PMID: 17360485]
HT-29	IC₅₀	0.15 μM Compound: 1, MLN-8054	Antiproliferative activity against human HT-29 cells after 4 days by celltiter assay Antiproliferative activity against human HT-29 cells after 4 days by celltiter assay	[PMID: 19402633]
MCF7	IC₅₀	0.67 μM Compound: MLN-8054	Antiproliferative activity against human MCF7 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human MCF7 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
MDA-MB-231	IC₅₀	0.74 μM Compound: MLN-8054	Antiproliferative activity against human MDAMB231 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human MDAMB231 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
NCI-H460	IC₅₀	0.11 μM Compound: MLN-8054	Antiproliferative activity against human H460 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human H460 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
PC-3	IC₅₀	0.79 μM Compound: MLN-8054	Antiproliferative activity against human PC3 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human PC3 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
Sf9	IC₅₀	0.004 μM Compound: MLN-8054	Inhibition of mouse recombinant Aurora A kinase expressed in insect Sf9 cells by radioactive flashplate assay Inhibition of mouse recombinant Aurora A kinase expressed in insect Sf9 cells by radioactive flashplate assay	[PMID: 17360485]
Sf9	IC₅₀	0.172 μM Compound: MLN-8054	Inhibition of mouse recombinant Aurora B kinase expressed in insect Sf9 cells by radioactive flashplate assay Inhibition of mouse recombinant Aurora B kinase expressed in insect Sf9 cells by radioactive flashplate assay	[PMID: 17360485]
Sf9	IC₅₀	172 nM Compound: MLN8054	Inhibition of mouse recombinant Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as substrate and [gamma33P]ATP by flashplate assay Inhibition of mouse recombinant Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as substrate and [gamma33P]ATP by flashplate assay	[PMID: 22803810]
Sf9	IC₅₀	172 nM Compound: MLN8054	Inhibition of GST-tagged recombinant mouse Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as peptide substrate by [gamma-33S]ATP binding assay Inhibition of GST-tagged recombinant mouse Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as peptide substrate by [gamma-33S]ATP binding assay	[PMID: 24681066]
Sf9	IC₅₀	31 nM Compound: 8, MLN8054	Inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells using biotin-GLRRASLG as substrate in presence of [gamma-33P]ATP Inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells using biotin-GLRRASLG as substrate in presence of [gamma-33P]ATP	[PMID: 26101564]
Sf9	IC₅₀	4 nM Compound: MLN8054	Inhibition of mouse recombinant Aurora A expressed in Sf9 cells using Biotin-GLRRASLG as substrate and [gamma33P]ATP by flashplate assay Inhibition of mouse recombinant Aurora A expressed in Sf9 cells using Biotin-GLRRASLG as substrate and [gamma33P]ATP by flashplate assay	[PMID: 22803810]
Sf9	IC₅₀	4 nM Compound: MLN8054	Inhibition of GST-tagged recombinant mouse Aurora A expressed in Sf9 cells using biotin-GLRRASLG as peptide substrate by [gamma-33S]ATP binding assay Inhibition of GST-tagged recombinant mouse Aurora A expressed in Sf9 cells using biotin-GLRRASLG as peptide substrate by [gamma-33S]ATP binding assay	[PMID: 24681066]
Sf9	IC₅₀	4 nM Compound: MLN8054	Inhibition of recombinant mouse Aurora A kinase expressed in Sf9 cells using Biotin-GLRRASLG as substrate in presence of [gamma33]P-ATP by FlashPlate assay Inhibition of recombinant mouse Aurora A kinase expressed in Sf9 cells using Biotin-GLRRASLG as substrate in presence of [gamma33]P-ATP by FlashPlate assay	[PMID: 30502115]
SK-OV-3	IC₅₀	0.53 μM Compound: MLN-8054	Antiproliferative activity against human SKOV3 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human SKOV3 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]
SW480	IC₅₀	0.86 μM Compound: MLN-8054	Antiproliferative activity against human SW480 cells after 96 hrs by BrdU cell proliferation ELISA Antiproliferative activity against human SW480 cells after 96 hrs by BrdU cell proliferation ELISA	[PMID: 17360485]

In Vitro

MLN8054 is an ATP-competitive, reversible inhibitor of recombinant Aurora A kinase. MLN8054 is >40-fold more selective for Aurora A compared with the family member Aurora B. MLN8054 selectively inhibits Aurora A over Aurora B in cultured human tumor cells. MLN8054 treatment results in G2/M accumulation and spindle defects and inhibits proliferation in multiple cultured human tumor cells lines. MLN8054 effectively inhibits the growth of cells from diverse tissue origins with IC₅₀ values ranging from 0.11 to 1.43 μM^[1]. Treatment of human tumor cells grown in culture with MLN8054 shows a number of morphologic and biochemical changes associated with senescence^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the HCT-116 tumor-bearing mice, MLN8054 treatment inhibits tumor growth dose dependently. MLN8054 is generally well tolerated. MLN8054 also inhibits the growth of the PC-3 tumor xenograft in nude mice. MLN8054 Treatment Results in Inhibition of Aurora A, Accumulation of Mitotic Cells, and Apoptosis in vivo^[1]. MLN8054 selectively inhibits Aurora A kinase activity when dosed at 30 mg/kg. At this dose in HCT116 tumor tissue, MLN8054 has been shown to inhibit Aurora A autophosphorylation, and induce an increase in the Aurora B substrate, pHisH3^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 869363-13-3
Appearance Solid
Peso molecular 476.86
Fòrmula C₂₅H₁₅ClF₂N₄O₂
Color White to yellow
SMILES

O=C(C1=CC=C(NC2=NC3=C(CN=C(C4=C3C=CC(Cl)=C4)C5=C(F)C=CC=C5F)C=N2)C=C1)O
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (10)

All

Sort by:

Journal Impact Factor

Cancer Res

Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells. [Abstract]

2017 Sep 15;77(18):4785-4796. PMID: 28720575
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
PLoS Biol

ULK1-ATG13 and their mitotic phospho-regulation by CDK1 connect autophagy to cell cycle. [Abstract]

2020 Jun 9;18(6):e3000288. PMID: 32516310
EMBO Rep

CK1-mediated phosphorylation of FAM110A promotes its interaction with mitotic spindle and controls chromosomal alignment. [Abstract]

2021 Jul 5;22(7):e51847. PMID: 34080749
Comput Struct Biotechnol J

Unveiling the Kinomes of Leishmania infantum and L. braziliensis Empowers the Discovery of New Kinase Targets and Antileishmanial Compounds. [Abstract]

2019 Feb 8:17:352-361. PMID: 30949306
Mol Cell Endocrinol

The N-terminal region of HASPIN regulates phosphorylation of AURKA and meiotic progression in spermatocytes. [Abstract]

2025 Aug 28:609:112645. PMID: 40885374
Anticancer Drugs

AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway. [Abstract]

2024 Jan 1;35(1):46-54. PMID: 37449977
Patent

US20210299273A1.
Technical University of Munich

24.01.2018.
J Biomol Screen

Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay. [Abstract]

2013 Oct;18(9):1062-71. PMID: 23788527

Solvente y solubilidad

In Vitro:

DMSO : 20.83 mg/mL (43.68 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0971 mL

10.4853 mL

20.9705 mL

5 mM

0.4194 mL

2.0971 mL

4.1941 mL

10 mM

0.2097 mL

1.0485 mL

2.0971 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.24 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[1]

MLN8054 is added to human tumor cells in 2-fold serial dilutions to achieve final concentrations ranging from 10 to 0.04 mM. MLN8054 at each dilution is added in triplicate with each replicate on a separate plate. Cells treated with DMSO (n=6 wells per plate; 0.2% final concentration) served as the untreated control. The cells are treated with MLN8054 for 96 h at 37°C in a humidified cell culture chamber. Cell viability in each cell line is measured by using the Cell Proliferation ELISA, BrdU colorimetric kit^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: Nude mice bearing HCT-116 tumors are treated orally once per day for 21 consecutive days with either vehicle control or MLN8054 at doses of 3, 10, or 30 mg/kg. Tumor volumes are measured by using a vernier caliper and calculated^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Manfredi MG, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11. [Content Brief]

[2]. Huck JJ, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 2010 Mar;8(3):373-84. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0971 mL	10.4853 mL	20.9705 mL	52.4263 mL
	5 mM	0.4194 mL	2.0971 mL	4.1941 mL	10.4853 mL
	10 mM	0.2097 mL	1.0485 mL	2.0971 mL	5.2426 mL
	15 mM	0.1398 mL	0.6990 mL	1.3980 mL	3.4951 mL
	20 mM	0.1049 mL	0.5243 mL	1.0485 mL	2.6213 mL
	25 mM	0.0839 mL	0.4194 mL	0.8388 mL	2.0971 mL
	30 mM	0.0699 mL	0.3495 mL	0.6990 mL	1.7475 mL
	40 mM	0.0524 mL	0.2621 mL	0.5243 mL	1.3107 mL

Keywords

MLN8054

10 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

MLN8054

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MLN8054

Ver todos los productos específicos de isoformas Aurora Kinase

Actividad biológica

Chemical Information

Publications (10)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

MLN8054

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MLN8054

Ver todos los productos específicos de isoformas Aurora Kinase

Actividad biológica

Chemical Information

Publications (10)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

MLN8054 Related Classifications

Referencia número: HY-10180